Literature DB >> 30892102

Cryo-thermal therapy inducing MI macrophage polarization created CXCL10 and IL-6-rich pro-inflammatory environment for CD4+ T cell-mediated anti-tumor immunity.

Ping Liu1, Shengguo Jia1, Yue Lou1, Kun He1, Lisa X Xu1.   

Abstract

PURPOSE: We previously developed a novel cryo-thermal therapy to treat malignant mammary carcinoma and melanoma in a mouse model; long-term survival and CD4+ T cell orchestrating anti-tumor immune memory response were achieved. Moreover, cryo-thermal-induced CD4+ T cell differentiation into Th1 and CD4+CTL sub-lineages, in which M1 macrophage polarization played a direct, important role. In particular, cryo-thermal therapy triggered M1 macrophage polarization with up-regulated expression of C-X-C motif ligand 10 (CXCL10) and Interleukin 6 (IL-6). But whether CXCL10 and IL-6 contribute to CD4+ T cell-mediated anti-tumor immunity remains unclear. In this study, the role of cryo-thermal-induced CXCL10 and IL-6 in anti-tumor immunity was determined.
METHODS: The level of CXCL10 and IL-6 in spleen and serum was determined by RT-PCR and ELISA on day 14 after cryo-thermal therapy. Splenic dendritic cells (DCs) and macrophages were isolated from cryo-thermal-treated mice on day 5 and 14, and the level of CXCL10 and IL-6 in macrophages and DCs was determined by ELISA. The transwell migration assay was performed to study immune cell migration. In vivo neutralization of CXCL10 or IL-6 was performed to investigate the phenotypic changes of immune cells.
RESULTS: Cryo-thermal therapy induced M1 macrophage polarization with up-regulation of CXCL10 and IL-6 expression in spleen. CXCL10 and IL-6 promoted DCs migration and maturation, and subsequently promoted CD4+ T cell migration and differentiation into Th1 and CD4+ CTL, moreover, reduced myeloid-derived suppressor cells (MDSCs) accumulation.
CONCLUSIONS: Cryo-thermal-induced CXCL10 and IL-6 created acute inflammatory environment to initiate a systemically cascading innate and adaptive anti-tumor immunity, which was more permissive for tumor eradication.

Entities:  

Keywords:  CD4 T cell differentiation; CXCL10; Cryo-thermal therapy; IL-6; M1 macrophages polarization

Year:  2019        PMID: 30892102     DOI: 10.1080/02656736.2019.1579373

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  6 in total

1.  Response of human macrophages to gamma radiation is mediated via expression of endogenous retroviruses.

Authors:  Natallia Mikhalkevich; Ina P O'Carroll; Rok Tkavc; Kateryna Lund; Gauthaman Sukumar; Clifton L Dalgard; Kory R Johnson; Wenxue Li; Tongguang Wang; Avindra Nath; Sergey Iordanskiy
Journal:  PLoS Pathog       Date:  2021-02-08       Impact factor: 6.823

2.  MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization.

Authors:  Jie Zhang; Yu Liu; Haiqiang Chen; Qi Yuan; Jinyan Wang; Meng Niu; Lingling Hou; Jianchun Gu; Jinhua Zhang
Journal:  Cell Death Dis       Date:  2022-04-28       Impact factor: 9.685

3.  Blood CDC42 overexpression is associated with an increased risk of acute exacerbation, inflammation and disease severity in patients with chronic obstructive pulmonary disease.

Authors:  Xiaoyan Ming; Fan Yang; Hong Zhu
Journal:  Exp Ther Med       Date:  2022-06-30       Impact factor: 2.751

4.  Th1-Dominant CD4+ T Cells Orchestrate Endogenous Systematic Antitumor Immune Memory After Cryo-Thermal Therapy.

Authors:  Peng Peng; Yue Lou; Junjun Wang; Shicheng Wang; Ping Liu; Lisa X Xu
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 5.  Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.

Authors:  Zihui Li; Jie Deng; Jianhai Sun; Yanling Ma
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

6.  CCL5 Deficiency Enhanced Cryo-Thermal-Triggered Long-Term Anti-Tumor Immunity in 4T1 Murine Breast Cancer.

Authors:  Yue Lou; Shengguo Jia; Ping Liu; Lisa X Xu
Journal:  Biomedicines       Date:  2022-02-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.